Dermatology Marketing Compliance: Medical, Cosmetic, and Skin Cancer Claims That Draw Enforcement

Dermatology practices typically offer a mix of medical dermatology (acne, psoriasis, eczema, skin cancer screening), cosmetic dermatology (neurotoxins, fillers, lasers, chemical peels), and increasingly retail or private-label skincare. Each category carries different compliance considerations, and the mix makes dermatology marketing one of the more complex healthcare marketing surfaces. This post covers the category-by-category framework.

Medical dermatology marketing

Disease-specific treatment claims

Skin cancer screening marketing

Skin cancer screening marketing is a specific category where FTC and state AGs have been active. Claims about detection rates, early-detection outcome benefits, and AI-assisted screening should be substantiated and framed carefully.

Prescription dermatology advertising

Branded prescription marketing (biologics like Dupixent, Humira; topicals like brand-name retinoids) falls under prescription drug advertising rules. Most dermatology practices don’t directly market these brands but do reference them in treatment discussions.

Cosmetic dermatology marketing

Cosmetic dermatology shares most of the med spa compliance framework - before/after imagery rules, injectable brand-name rules, device FDA-cleared/approved distinctions, typical-experience disclosure. See our med spa compliance post for the detailed framework that applies.

Specialty-specific considerations

• Board-certified dermatologist marketing.ABD certification is widely recognized and supportable when accurately stated.
• Cosmetic specialty framing.Dermatologists legitimately offer cosmetic services within their scope; “cosmetic dermatologist” is defensible with appropriate backing.
• Physician-performed vs delegated procedures.Clear marketing of who performs what matters both for consumer understanding and for state medical board compliance.

Retail and private-label skincare

Many dermatology practices sell retail skincare or private- label lines. Cosmetic labeling and claim rules apply:

Cosmetic vs drug boundary

“Medical-grade” and “cosmeceutical”

Neither term has specific FDA definition. Using them in marketing creates an implication of regulatory status that doesn’t exist. Specific framing (“professional-strength,” “clinical-grade formulation”) is typically less problematic than implying FDA endorsement.

Ingredient claims

Specific ingredient outcome claims (“retinol reverses aging,” “vitamin C brightens”) need substantiation. Ingredient-level claims can be more substantiable than product-level claims because research on specific ingredients is often robust.

Teledermatology marketing

Teledermatology adds telehealth-specific rules on top of general dermatology compliance:

• State licensure.Teledermatology to patients requires provider licensure in the patient’s state.
• Examination standards. Marketing that minimizes clinical evaluation has drawn state board attention.
• Prescribing rules. Prescription-based teledermatology faces controlled-substance and store-and-forward rules depending on the prescriptions.
• Asynchronous vs synchronous. Marketing should accurately describe the actual service model.

Common mistakes specific to dermatology marketing

Mistake 1: Conflating cosmetic and medical in claims

Dermatology practices legitimately offer both but sometimes blur the lines in marketing in ways that create regulatory overlap. Medical and cosmetic framings each have their own compliance considerations, and marketing should respect the boundary.

Mistake 2: Skin cancer scare-based marketing

Scare-marketing around skin cancer (“don’t wait, skin cancer kills”) triggers consumer-protection scrutiny when it’s paired with promotional offers for screening. Informational content about skin cancer is fine; fear-based conversion tactics face additional scrutiny.

Mistake 3: Private-label supplement line marketing

Dermatology practices selling private-label supplement lines for skin, hair, or nail health face DSHEA rules plus FDA drug-claim concerns on disease claims. Supplement marketing alongside clinical services creates documentation and claim challenges.

Mistake 4: Before/after without medical dermatology context

Before/after imagery for medical dermatology (acne, rosacea, psoriasis) often lacks the clinical context and individual- variation framing that medical marketing requires. Treat medical dermatology before/after with the same rigor as cosmetic dermatology before/after.

Frequently asked questions

Can I market non-FDA-approved off-label uses?

Clinical off-label use is standard practice; marketing specific off-label uses is a regulatory risk. For dermatology, this often involves biologics used for conditions beyond their labeled indications.

What about cosmetic claim substantiation?

Cosmetic claims still need substantiation under FTC rules, though the evidentiary bar is less strict than for drug claims. Specific outcome claims (“reduces wrinkles by X%”) need supporting evidence.

Does physician endorsement of products create material connection?

If the physician has a financial interest in the product, yes - and the relationship should be disclosed in the endorsement. This is common in private-label situations and is sometimes missed in disclosure practice.

How do I handle prescription-related content?

General patient education about conditions and treatment categories is generally lower-risk. Specific prescription-drug promotion by brand name falls under prescription advertising rules with fair-balance requirements.

What about social media aesthetic content from dermatologists?

Dermatologists’ personal and professional social media content discussing their practice is subject to the same rules as the practice’s official marketing. Personal accounts that discuss practice services aren’t exempt.

Are there derm-specific insurance considerations?

Dermatology malpractice insurance may have specific provisions about cosmetic vs medical practice scope. Advertising exposure (FTC claims, private class action) is typically covered differently than malpractice. Review policies specifically.